Published in Mol Endocrinol on June 01, 2002
Involution of the mouse mammary gland is associated with an immune cascade and an acute-phase response, involving LBP, CD14 and STAT3. Breast Cancer Res (2003) 2.48
Gene expression profiling of mammary gland development reveals putative roles for death receptors and immune mediators in post-lactational regression. Breast Cancer Res (2003) 2.29
Computational expression deconvolution in a complex mammalian organ. BMC Bioinformatics (2006) 2.18
SNORD-host RNA Zfas1 is a regulator of mammary development and a potential marker for breast cancer. RNA (2011) 2.03
Cyclin D1 determines mitochondrial function in vivo. Mol Cell Biol (2006) 1.75
Identification of hair cycle-associated genes from time-course gene expression profile data by using replicate variance. Proc Natl Acad Sci U S A (2004) 1.36
Cellular origins of cold-induced brown adipocytes in adult mice. FASEB J (2014) 1.34
Macrophages in breast cancer: do involution macrophages account for the poor prognosis of pregnancy-associated breast cancer? J Mammary Gland Biol Neoplasia (2009) 1.31
Gene regulatory networks in lactation: identification of global principles using bioinformatics. BMC Syst Biol (2007) 1.23
Steroid receptor RNA activator stimulates proliferation as well as apoptosis in vivo. Mol Cell Biol (2003) 1.22
Characterisation of microRNA expression in post-natal mouse mammary gland development. BMC Genomics (2009) 1.21
Key signalling nodes in mammary gland development and cancer: Myc. Breast Cancer Res (2009) 1.19
MiDReG: a method of mining developmentally regulated genes using Boolean implications. Proc Natl Acad Sci U S A (2010) 1.15
Dissecting the roles of beta-catenin and cyclin D1 during mammary development and neoplasia. Proc Natl Acad Sci U S A (2003) 1.08
Diverse and active roles for adipocytes during mammary gland growth and function. J Mammary Gland Biol Neoplasia (2010) 1.07
Patterns of cell signaling pathway activation that characterize mammary development. Development (2008) 1.02
c-Myc affects mRNA translation, cell proliferation and progenitor cell function in the mammary gland. BMC Biol (2009) 0.96
Analysis of gene expression in PTHrP-/- mammary buds supports a role for BMP signaling and MMP2 in the initiation of ductal morphogenesis. Dev Dyn (2009) 0.91
Genes of the RNASE5 pathway contain SNP associated with milk production traits in dairy cattle. Genet Sel Evol (2013) 0.91
Genomic analysis of early murine mammary gland development using novel probe-level algorithms. Genome Biol (2005) 0.89
Profile of estrogen-responsive genes in an estrogen-specific mammary gland outgrowth model. Mol Reprod Dev (2009) 0.88
Microdissection of the gene expression codes driving nephrogenesis. Organogenesis (2011) 0.80
Abnormal Mammary Adipose Tissue Environment of Brca1 Mutant Mice Show a Persistent Deposition of Highly Vascularized Multilocular Adipocytes. J Cancer Sci Ther (2011) 0.79
Global expression profiling reveals regulation of CTGF/CCN2 during lactogenic differentiation. J Cell Commun Signal (2009) 0.79
Increased Expression of Beige/Brown Adipose Markers from Host and Breast Cancer Cells Influence Xenograft Formation in Mice. Mol Cancer Res (2015) 0.79
Development of Foreign Mammary Epithelial Morphology in the Stroma of Immunodeficient Mice. PLoS One (2013) 0.78
A pilot study of FDG PET/CT detects a link between brown adipose tissue and breast cancer. BMC Cancer (2014) 0.78
Mammary fat of breast cancer: gene expression profiling and functional characterization. PLoS One (2014) 0.78
MK886 inhibits the pioglitazone-induced anti-invasion of MDA-MB-231 cells is associated with PPARα/γ, FGF4 and 5LOX. Cytotechnology (2016) 0.77
Miz1 deficiency in the mammary gland causes a lactation defect by attenuated Stat5 expression and phosphorylation. PLoS One (2014) 0.77
Functional roles of MMP14 and MMP15 in early postnatal mammary gland development. Development (2016) 0.75
Evolving views of involution. Breast Cancer Res (2004) 0.75
LPA receptor activity is basal specific and coincident with early pregnancy and involution during mammary gland postnatal development. Sci Rep (2016) 0.75
Control of Hoxd gene transcription in the mammary bud by hijacking a preexisting regulatory landscape. Proc Natl Acad Sci U S A (2016) 0.75
A prognosis classifier for breast cancer based on conserved gene regulation between mammary gland development and tumorigenesis: a multiscale statistical model. PLoS One (2013) 0.75
Comparative transcriptome analyses reveal conserved and distinct mechanisms in ovine and bovine lactation. Funct Integr Genomics (2013) 0.75
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol (2003) 8.12
Human epicardial adipose tissue is a source of inflammatory mediators. Circulation (2003) 6.31
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet (2009) 5.82
The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell (2005) 5.81
Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst (2011) 5.79
Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol (2007) 4.67
Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell (2002) 4.36
Global regulation of erythroid gene expression by transcription factor GATA-1. Blood (2004) 4.22
The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev (2003) 3.79
Should randomized clinical trials be required for proton radiotherapy? J Clin Oncol (2008) 3.72
Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. J Proteome Res (2007) 3.48
Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys (2005) 3.19
A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology. FASEB J (2002) 3.05
Estimation of α/β for late rectal toxicity based on RTOG 94-06. Int J Radiat Oncol Biol Phys (2011) 2.96
A targeted proteomics-based pipeline for verification of biomarkers in plasma. Nat Biotechnol (2011) 2.91
CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest (2011) 2.90
Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2006) 2.90
Hlx is induced by and genetically interacts with T-bet to promote heritable T(H)1 gene induction. Nat Immunol (2002) 2.87
Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys (2006) 2.82
4D Proton treatment planning strategy for mobile lung tumors. Int J Radiat Oncol Biol Phys (2007) 2.80
Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. J Clin Oncol (2009) 2.75
mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging. Cell Stem Cell (2009) 2.74
Differential regulation of the transcriptional activities of hypoxia-inducible factor 1 alpha (HIF-1alpha) and HIF-2alpha in stem cells. Mol Cell Biol (2006) 2.56
GATA-1-mediated proliferation arrest during erythroid maturation. Mol Cell Biol (2003) 2.52
Assessing respiration-induced tumor motion and internal target volume using four-dimensional computed tomography for radiotherapy of lung cancer. Int J Radiat Oncol Biol Phys (2007) 2.35
[18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol (2005) 2.30
Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys (2007) 2.28
Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev (2003) 2.27
Computational expression deconvolution in a complex mammalian organ. BMC Bioinformatics (2006) 2.18
The Ets transcription factor Elf5 specifies mammary alveolar cell fate. Genes Dev (2008) 2.13
Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study. Int J Radiat Oncol Biol Phys (2009) 2.08
Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell (2004) 2.08
Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Cancer Res (2007) 2.03
Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys (2009) 2.01
Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2004) 1.94
Image-guided radiation therapy for non-small cell lung cancer. J Thorac Oncol (2008) 1.90
Implementation and validation of a three-dimensional deformable registration algorithm for targeted prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys (2005) 1.87
HIF-2alpha deletion promotes Kras-driven lung tumor development. Proc Natl Acad Sci U S A (2010) 1.86
Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). Int J Radiat Oncol Biol Phys (2002) 1.85
Conditional overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors. Cancer Res (2004) 1.84
The risk of developing a second cancer after receiving craniospinal proton irradiation. Phys Med Biol (2009) 1.83
Assessment of gross tumor volume regression and motion changes during radiotherapy for non-small-cell lung cancer as measured by four-dimensional computed tomography. Int J Radiat Oncol Biol Phys (2007) 1.74
Analysis of cell migration using whole-genome expression profiling of migratory cells in the Drosophila ovary. Dev Cell (2006) 1.73
Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2004) 1.73
Esophageal cancer dose escalation using a simultaneous integrated boost technique. Int J Radiat Oncol Biol Phys (2010) 1.72
Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition. J Clin Invest (2009) 1.67
Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys (2012) 1.65
Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys (2005) 1.63
Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer (2011) 1.63
Are the results of RTOG 0617 mysterious? Int J Radiat Oncol Biol Phys (2012) 1.60
Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy. J Clin Invest (2015) 1.58
Effects of interfractional motion and anatomic changes on proton therapy dose distribution in lung cancer. Int J Radiat Oncol Biol Phys (2008) 1.56
Status of particle therapy for lung cancer. Acta Oncol (2011) 1.56
Persistent parity-induced changes in growth factors, TGF-beta3, and differentiation in the rodent mammary gland. Mol Endocrinol (2002) 1.56
Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: how do protons compare with other conformal techniques? Int J Radiat Oncol Biol Phys (2005) 1.55
Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. Radiother Oncol (2005) 1.53
Bcl-X(L) affects Ca(2+) homeostasis by altering expression of inositol 1,4,5-trisphosphate receptors. Proc Natl Acad Sci U S A (2002) 1.51
PET imaging of glutaminolysis in tumors by 18F-(2S,4R)4-fluoroglutamine. J Nucl Med (2011) 1.50
c-Myc transforms human mammary epithelial cells through repression of the Wnt inhibitors DKK1 and SFRP1. Mol Cell Biol (2007) 1.50
Deregulated estrogen receptor alpha expression in mammary epithelial cells of transgenic mice results in the development of ductal carcinoma in situ. Cancer Res (2005) 1.46
Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters. Int J Radiat Oncol Biol Phys (2003) 1.45
Radiotherapy alone for lymphocyte-predominant Hodgkin's disease. Cancer J (2002) 1.45
Assessment of technological advances in radiation oncology: from whence comes the funding? Int J Radiat Oncol Biol Phys (2008) 1.44
Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis. Int J Radiat Oncol Biol Phys (2012) 1.43
Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. Int J Radiat Oncol Biol Phys (2005) 1.42
Reduction of normal lung irradiation in locally advanced non-small-cell lung cancer patients, using ventilation images for functional avoidance. Int J Radiat Oncol Biol Phys (2007) 1.42
Four-dimensional computed tomography-based treatment planning for intensity-modulated radiation therapy and proton therapy for distal esophageal cancer. Int J Radiat Oncol Biol Phys (2008) 1.41
Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: findings from a prospective, multi-institutional, phase I/II dose-escalation study. Int J Radiat Oncol Biol Phys (2004) 1.40
Effect of anatomic motion on proton therapy dose distributions in prostate cancer treatment. Int J Radiat Oncol Biol Phys (2007) 1.40
Dose-volume thresholds and smoking status for the risk of treatment-related pneumonitis in inoperable non-small cell lung cancer treated with definitive radiotherapy. Radiother Oncol (2008) 1.40
Krüppel-like factor 4 inhibits tumorigenic progression and metastasis in a mouse model of breast cancer. Neoplasia (2011) 1.39
A lysosomal tetraspanin associated with retinal degeneration identified via a genome-wide screen. EMBO J (2004) 1.39
Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience. Int J Radiat Oncol Biol Phys (2011) 1.37
Isoform-specific requirement for Akt1 in the developmental regulation of cellular metabolism during lactation. Cell Metab (2006) 1.36
International prognostic index-based outcomes for diffuse large B-cell lymphomas. Cancer (2002) 1.36
Tumor escape in a Wnt1-dependent mouse breast cancer model is enabled by p19Arf/p53 pathway lesions but not p16 Ink4a loss. J Clin Invest (2008) 1.36
Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study. Int J Radiat Oncol Biol Phys (2010) 1.35
Isoform-specific ras activation and oncogene dependence during MYC- and Wnt-induced mammary tumorigenesis. Mol Cell Biol (2006) 1.34
Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. Int J Radiat Oncol Biol Phys (2008) 1.32
Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys (2011) 1.32
Hormone-induced protection against mammary tumorigenesis is conserved in multiple rat strains and identifies a core gene expression signature induced by pregnancy. Cancer Res (2006) 1.30